(Press-News.org) Sophia Antipolis, 26 April 2013. A practical guide on the use of the new oral anticoagulants (NOACs) has been produced by the European Heart Rhythm Association (EHRA) of the European Society of Cardiology (ESC). A guide was needed to summarise existing information on different drugs, to answer clinical questions that fall outside what drug companies can legally answer, and to make distinctions between the different drugs.
ESC guidelines on atrial fibrillation recommend the NOACs as preferable to vitamin K antagonists for stroke prevention in patients with non-valvular atrial fibrillation.1 Companies provide a Summary of Product Characteristics (SmPC) for their drug but the content is bound by legal restrictions and the information in SmPCs for different NOACs overlaps.
Professor Hein Heidbuchel (Belgium), lead author of the EHRA guide, said: "Companies are bound by legal restrictions in their SmPCs and for physicians in the field the information is often not specific enough. EHRA goes further than the SmPCs and provides expert guidance, often admittedly based on incomplete data, on what to do in specific clinical situations."
He added: "We have brought together information on all the NOACs in one document so it's clear for physicians what the similarities and differences are. We worked closely with the drug companies to make sure that all of the information in the SmPCs is also in our document."
The paper provides practical advice on how to handle 15 clinical scenarios. The full paper is published today in EHRA's official journal, EP-Europace,2 and the executive summary is published online in European Heart Journal.3
The clinical situations include how to initiate and monitor NOAC use, how to measure the anticoagulant effect if needed in specific situations, switching between anticoagulants, ensuring compliance, patients with chronic kidney disease and management of bleeding complications.
NOACs remove the regular monitoring of anticoagulation level that was required for the vitamin K antagonists. But Professor Heidbuchel said: "Compliance is very important for the novel anticoagulant drugs because they have a very short half-life. That means that if you don't take them you will not be protected by anticoagulation and are at greater risk of thromboembolic events."
The document provides tips on how to improve compliance. These include educating patients about the drug's short half-life, and that small minor bleeding such as a nose bleed will stop by itself and patients should continue taking the drug. Compliance can also be improved with a pre-specified follow up scheme.
The guide does not cover the indications for switching from a vitamin K antagonist to a NOAC but it does advise how to switch safely. Professor Heidbuchel said: "We have learned from the big trials that these moments of transitioning from one anticoagulant to another can be dangerous in the sense that patients can be under-anticoagulated."
He added: "The bleeding risk profile of the NOACs is definitely better than that of vitamin K antagonists. Nevertheless bleedings will occur and so our practical document has outlined what action should be taken."
Professor Stefan Hohnloser (Germany), a reviewer of the EHRA guide and a member of the ESC atrial fibrillation guidelines task force, said: "The updated ESC guidelines on the treatment of atrial fibrillation recommend the NOACs to be used rather than the vitamin K antagonists. Like all new drugs these drugs have pitfalls – for example they are excreted via the kidneys and therefore physicians need to measure renal function regularly. Physicians who follow the practical advice in this guide will dramatically improve the safety of their patients."
###
New information on the NOACs is rapidly becoming available and EHRA has developed a website with the latest information, http://www.NOACforAF.eu (link will become available when the embargo is lifted).
References
1. Camm AJ, Lip GYH, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. European Heart Journal. 2012; 33:2719-2747.
2. Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2013; 15:625-651, DOI: 10.1093/europace/eut083
3. Heidbuchel H, Verhamme P, Alings M, et Al. EHRA practical guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Advance Access published, European Heart Journal.213; DOI: 10.1093/eurheartj/eht134
Notes to Editors:
About the European Society of Cardiology (ESC)
The European Society of Cardiology (ESC) represents 80,000 cardiology professionals across Europe and the Mediterranean. Its mission is to reduce the burden of cardiovascular disease in Europe.
About the European Heart Rhythm Association (EHRA)
The European Heart Rhythm Association (EHRA) is a registered branch of the ESC. Its aim is to improve the quality of life of the European population by reducing the impact of cardiac arrhythmias and reducing sudden cardiac death.
About the European Heart Journal (EHJ)
The European Heart Journal is the flagship journal of the European Society of Cardiology. It is published on behalf of the ESC by Oxford Journals, a division of Oxford University Press. Please acknowledge the journal as a source in any articles.
About EP Europace
Official journal of the European Heart Rhythm Association and the ESC Working Group on Cardiac Cellular Electrophysiology. EP Europace is also an official journal of the ESC Working Group on e-Cardiology
ESC guide on new oral anticoagulant drugs
2013-04-26
ELSE PRESS RELEASES FROM THIS DATE:
Cardio could hold key to cancer cure
2013-04-26
Amsterdam, The Netherlands, Friday 26 April 2013: Regular exercise has been proven to reduce the chance of developing liver cancer in a world-first mice study that carries hope for patients at risk from hepatocellular carcinoma (HCC).
The research announced at the International Liver Congress™ 2013 involved two groups of mice fed a control diet and a high fat diet then divided into separate exercise and sedentary groups. The exercise groups ran on a motorised treadmill for 60 minutes per day, five days a week.
After 32 weeks of regular exercise, 71% of mice on the ...
New 10-year risk predictors identified for liver related
2013-04-26
Amsterdam, The Netherlands, Friday 26 April 2013: A study presented today at the International Liver CongressTM 2013 – which evaluated the relationship between non-alcoholic fatty liver disease (NAFLD), early predictors of atherosclerosis and the 10-year Framingham risk score (FRS) – showed that NAFLD increases the risk of early atherosclerotic lesions independent of established cardiovascular (CV) risk factors.
NAFLD is one of the most common causes of chronic liver disease. Patients with NAFLD have an excess prevalence of CV events and typically have an increase frequency ...
Developments in TACE and SIRT treatment in patients
2013-04-26
Amsterdam, The Netherlands, Friday 26 April 2013: Data from a number of clinical trials presented today at the International Liver Congress™ 2013 shed new light on the use of TACE and SIRT in the treatment of hepatocellular carcinoma (HCC).
Transarterial chemoembolization (TACE) is a technique in which small particles designed to block blood vessels mixed or coated with chemotherapeutic drugs are injected directly into an artery supplying the tumour; it has become a standard treatment in selected patients with HCC.
New data presented today has identified a scoring system ...
Learning disabilities affect up to 10 percent of children and co-occur at higher than expected rates
2013-04-26
Up to 10 per cent of the population is affected by specific learning disabilities (SLDs), such as dyslexia, dyscalculia and autism, translating to two or three pupils in every classroom, a new study has found.
Led by Professor Brian Butterworth, a Professorial Fellow at the University of Melbourne's School of Psychological Sciences and Emeritus Professor of cognitive neuropsychology at University College London, the study gives insight into the underlying causes of specific learning disabilities and how to tailor individual teaching and learning for individuals and education ...
Movement of pyrrole molecules defy 'classical' physics
2013-04-26
New research shows that movement of the ring-like molecule pyrrole over a metal surface runs counter to the centuries-old laws of 'classical' physics that govern our everyday world.
Using uniquely sensitive experimental techniques, scientists have found that laws of quantum physics - believed primarily to influence at only sub-atomic levels – can actually impact on a molecular level.
Researchers at Cambridge's Chemistry Department and Cavendish Laboratory say they have evidence that, in the case of pyrrole, quantum laws affecting the internal motions of the molecule ...
Fish win fights on strength of personality
2013-04-26
When predicting the outcome of a fight, the big guy doesn't always win suggests new research on fish. Scientists at the University of Exeter and Texas A&M University found that when fish fight over food, it is personality, rather than size, that determines whether they will be victorious. The findings suggest that when resources are in short supply personality traits such as aggression could be more important than strength when it comes to survival.
The study, published in the journal Behavioral Ecology and Sociobiology, found that small fish were able to do well in contests ...
Forthcoming study explores use of intermittent fasting in diabetes as cardiovascular disease
2013-04-26
Los Angeles, CA (April 26, 2013) – Intermittent fasting is all the rage, but scientific evidence showing how such regimes affect human health is not always clear cut. Now a scientific review in the British Journal of Diabetes and Vascular Disease published by SAGE, suggests that fasting diets may help those with diabetes and cardiovascular disease, alongside established weight loss claims.
Intermittent fasting –fasting on a given number of consecutive or alternate days – has recently been hailed as a path to weight loss and improved cardiovascular risk. A team led by ...
Flu and bacteria: Better prognosis for this potentially fatal combination
2013-04-26
This press release is available in German.
The flu is caused by an infection with the influenza virus, which mainly attacks the upper respiratory tract – the nose, throat and bronchi and rarely also the lungs. According to the World Health Organization (WHO), around five to 15 percent of the population are affected by upper respiratory tract infections during seasonal flu outbreaks, and between 250 000-500 000 people die of the illness every year. However, a main cause of death in people having the flu is actually a secondary infection with bacteria.
Influenza increases ...
Developmental neurobiology: How the brain folds to fit
2013-04-26
During fetal development of the mammalian brain, the cerebral cortex undergoes a marked expansion in surface area in some species, which is accommodated by folding of the tissue in species with most expanded neuron numbers and surface area. Researchers have now identified a key regulator of this crucial process.
Different regions of the mammalian brain are devoted to the performance of specific tasks. This in turn imposes particular demands on their development and structural organization. In the vertebrate forebrain, for instance, the cerebral cortex – which is responsible ...
Using mobile phone apps in weight-loss programs
2013-04-26
Mobile phones using text messaging and monitoring have been shown to be useful additions to health programs. The objective of this study was to develop and evaluate a weight-loss intervention delivered by a smartphone app that supported individuals embarking on a diet and that was evidenced-based. Researchers developed and tested a mobile phone application (app) to support individuals embarking on a partial meal replacement program (MRP).
Overweight or obese women were randomly allocated to one of two study groups an intervention group and a control group. The intervention ...